Accutar Biotechnology discovers SOS1 inhibitors for cancer
June 27, 2024
Accutar Biotechnology Inc. has patented new substituted quinoline derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.